Tirzepatide
Sold as Mounjaro and Zepbound, this is one of the most effective weight loss medications available. It works by targeting two appetite hormones at once (GIP and GLP-1), making it more powerful than medications like semaglutide that only target one. People in clinical trials lost up to 22.5% of their body weight. Also FDA-approved for type 2 diabetes, and improves cholesterol and blood fat levels.
Tirzepatide is a first-in-class dual GIP/GLP-1 receptor agonist developed by Eli Lilly. It is available as Mounjaro (for type 2 diabetes) and Zepbound (for weight management), both administered as once-weekly subcutaneous injections. In the SURMOUNT clinical trials, tirzepatide produced weight loss of 20-22% of body weight at the highest dose — the most effective pharmaceutical weight loss ever recorded in clinical trials.
What sets tirzepatide apart is its dual mechanism. While semaglutide activates only GLP-1 receptors, tirzepatide simultaneously activates both GLP-1 and GIP (glucose-dependent insulinotropic polypeptide) receptors. The GIP component provides additional insulin sensitization, enhanced fat metabolism, and potentially direct effects on adipose tissue that contribute to greater weight loss and better glycemic control than GLP-1 agonists alone.
Tirzepatide has shown HbA1c reductions of 2.0-2.4% in diabetes trials — significantly more than any other injectable diabetes medication. It is currently being studied for heart failure, sleep apnea, and NAFLD. The side effect profile is similar to other GLP-1 agonists (primarily gastrointestinal), though the nausea rate appears slightly lower than semaglutide, possibly due to GIP's gastroprotective effects.
Dosage
5-15 mg subcutaneous once weekly (maintenance)
Dosages shown are for research reference only. Always consult a qualified healthcare provider.
Administration
Subcutaneous injection (weekly)
Get Research-Grade Tirzepatide
99%+ purity · US-based · third-party lab tested
Getting Started — Here's What You'll Need
Effects
Weight Loss
Up to 22.5% body weight reduction at highest dose — superior to single-target GLP-1 agonists.
Appetite Suppression
Dual GIP/GLP-1 pathway activation provides amplified appetite control.
Blood Sugar Control
Dual incretin action produces robust insulin response and HbA1c reduction.
Lipid Improvement
Reduces triglycerides and improves overall lipid profile through enhanced lipid metabolism.
Mechanism of Action
Tirzepatide is the first approved dual incretin receptor agonist, simultaneously activating both GIP (glucose-dependent insulinotropic polypeptide) and GLP-1 receptors. This dual mechanism represents a paradigm shift in obesity and diabetes treatment because the two receptor systems produce complementary and additive metabolic effects that neither achieves alone.
The GLP-1 receptor component works similarly to semaglutide — suppressing appetite through hypothalamic signaling, slowing gastric emptying, and stimulating glucose-dependent insulin secretion. However, the addition of GIP receptor agonism provides unique benefits. GIP receptors in adipose tissue enhance lipid metabolism and may improve fat storage efficiency, while GIP signaling in the brain appears to amplify the appetite-suppressing effects of GLP-1 through distinct neuronal circuits in the hypothalamus.
At the pancreatic level, the dual stimulation of both GIP and GLP-1 receptors on beta cells produces a more robust insulin secretory response than either pathway alone. Tirzepatide also improves insulin sensitivity in peripheral tissues, reduces hepatic fat content, and lowers triglyceride levels. The molecule is built on a modified GIP peptide backbone with GLP-1 receptor cross-reactivity, attached to a C20 fatty di-acid moiety that enables albumin binding and weekly dosing. Clinical trials have shown weight loss of up to 22.5% of body weight, surpassing GLP-1-only agents.
Regulatory Status
FDA approved. Mounjaro (2022), Zepbound (2023). Eli Lilly. Subject to intermittent supply shortages.
Risks & Safety
Common
nausea (25-35%), diarrhea, constipation, vomiting, reduced appetite, stomach pain, redness at injection site.
Serious
inflammation of the pancreas (pancreatitis), gallstones, very slow stomach emptying (gastroparesis), low blood sugar if combined with other diabetes medications.
Rare
thyroid tumours seen in animal studies, severe allergic reactions, kidney problems.
Compare Tirzepatide With
Research Papers
30Published: February 11, 2026
AI Summary
The Sim-Q questionnaire was validated to measure how simple or complex type 2 diabetes treatment feels to patients. The tool may help compare newer once-weekly drugs like tirzepatide with older regimens.
Published: February 11, 2026
AI Summary
Breast cancer survivors on GLP-1 drugs like semaglutide or tirzepatide lost modest weight and had better overall survival than matched non-users in a real-world study. The drugs did not affect disease-free survival.
Published: February 1, 2026
AI Summary
A network meta-analysis compared tirzepatide and semaglutide for weight loss and blood sugar control. The abstract states the aim; full results would show which drug performs better for obesity.
Published: February 8, 2026
AI Summary
Peptide drugs often have short half-lives, but chemical tweaks like fatty-acid attachment can extend them and allow weekly dosing. The review explains how peptide pharmacokinetics scale across species.
Published: February 5, 2026
AI Summary
Tirzepatide's effects on the eyes remain poorly understood compared with other GLP-1 drugs. The abstract notes the need to characterize its ocular safety profile.
Published: February 6, 2026
AI Summary
GLP-1 drugs lower blood sugar and weight, but their impact on bone in fracture-prone patients is unclear. The abstract states the aim; full findings would clarify fracture risk.
Published: February 7, 2026
AI Summary
A fluorescent probe method was developed to measure tirzepatide in drugs and blood with high sensitivity and precision. The approach may support quality control and pharmacokinetic studies.
Published: February 2, 2026
AI Summary
Switching from semaglutide to tirzepatide led to lithium toxicity in a case report, likely by changing how lithium is absorbed or cleared. The case highlights the need to monitor other drugs when changing GLP-1 therapy.
Published: February 3, 2026
AI Summary
A planned trial will test whether giving tirzepatide before weight-loss surgery improves preoperative weight loss and reduces tissue inflammation, leading to better surgical outcomes.
Published: September 28, 2026
AI Summary
Two case reports showed that GLP-1 drugs affected body composition differently in older women. The abstract highlights the need to understand their impact on lean mass in aging.
Published: December 1, 2025
AI Summary
Russian experts developed a consensus algorithm for choosing tirzepatide or semaglutide in patients with overweight, obesity, or type 2 diabetes. The goal is to guide effective use in local practice.
Published: February 1, 2026
AI Summary
A review covers lifestyle, GLP-1 drugs including tirzepatide, and surgery for obesity in psoriasis patients. It offers clinic-level algorithms to help dermatologists manage weight in this population.
Published: February 1, 2026
AI Summary
Despite the rise of GLP-1 drugs, weight-loss surgery remains the most effective obesity treatment. The review discusses how to improve both drug and surgical outcomes and why surgery will stay central.
Published: January 13, 2025
AI Summary
Real-world data suggest the Mediterranean diet may enhance tirzepatide's effects on belly fat and insulin resistance beyond weight loss alone. Diet quality could modulate the drug's benefits.
Published: February 27, 2026
AI Summary
A man on tirzepatide, intermittent fasting, and a low-carb diet developed dangerous ketoacidosis despite normal blood sugar. The case underscores the need for medical supervision when combining these approaches.
Published: April 15, 2026
AI Summary
A clinician guide explains how to address patient concerns about GLP-1 drugs being "new" or unsafe. It outlines the long history of GLP-1 research and practical counseling tips for shared decision-making.
Published: January 27, 2026
AI Summary
A review compares liraglutide, semaglutide, and tirzepatide for obesity in non-diabetic patients, including cost-effectiveness and clinical trends. All three are approved for weight management.
Published: January 5, 2026
AI Summary
GLP-1 drug use was linked to roughly half the risk of pancreatic cancer in chronic pancreatitis patients. The finding may support their use in this high-risk group, though prospective studies are needed.
Published: February 25, 2026
AI Summary
In obese mice, tirzepatide activated brown fat and improved glucose tolerance beyond what could be explained by reduced food intake. The drug may have direct metabolic effects on fat tissue.
Published: January 25, 2026
AI Summary
A meta-analysis examined how GLP-1 drugs affect heart rate in overweight or obese people without diabetes. The abstract states the aim; full results would clarify whether they raise heart rate.
Published: January 22, 2026
AI Summary
Short-term GLP-1 use may preserve muscle strength despite lean mass loss, but longer use in older adults with diabetes has been linked to weaker grip and faster sarcopenia. More trials in older patients are needed.
Published: January 19, 2026
AI Summary
G protein-biased GLP-1 agonists like tirzepatide show favorable clinical profiles. Mutations that mimic this bias without changing the drug helped clarify how bias affects efficacy.
Published: January 8, 2026
AI Summary
Tirzepatide may help heart failure with preserved ejection fraction by cutting weight, improving lipids and blood pressure, and reducing inflammation. The review outlines mechanisms and implications for care.
Published: February 23, 2026
AI Summary
GLP-1 drugs are linked to vitamin D, iron, calcium, and other nutrient deficiencies, partly due to appetite suppression and delayed stomach emptying. The review recommends targeted nutritional assessment for at-risk users.
Published: March 4, 2026
AI Summary
Dual and triple incretin drugs like tirzepatide and retatrutide are changing treatment for diabetes, obesity, and fatty liver. The review summarizes their mechanisms, clinical progress, and remaining challenges.
Published: January 13, 2026
AI Summary
Real-world data compared tirzepatide, semaglutide, and SGLT2 inhibitors for dementia risk in type 2 diabetes. The abstract describes the design; full results would show whether tirzepatide affects dementia.
Published: January 14, 2026
AI Summary
A 2026 study protocol will track weight loss, side effects, and rebound in patients on semaglutide or tirzepatide versus lifestyle-only, and provide health education on diet and exercise during treatment.
Published: January 14, 2026
AI Summary
Patients on tirzepatide who engaged more with a digital weight-loss platform lost more weight. Digital coaching and self-monitoring may boost the drug's real-world effectiveness.
Published: January 13, 2026
AI Summary
Two women with chronic hives that resisted antihistamines saw complete remission within weeks of starting semaglutide or tirzepatide. The findings suggest GLP-1 drugs may help mast cell-driven skin disease.
Published: February 1, 2026
AI Summary
A pharmacovigilance study and literature review evaluated whether GLP-1 drugs are linked to Wernicke encephalopathy from thiamine deficiency. The abstract states the aim; full results would clarify the risk.
Frequently Asked Questions
What is Tirzepatide?
Sold as Mounjaro and Zepbound, this is one of the most effective weight loss medications available. It works by targeting two appetite hormones at once (GIP and GLP-1), making it more powerful than medications like semaglutide that only target one. People in clinical trials lost up to 22.5% of their body weight. Also FDA-approved for type 2 diabetes, and improves cholesterol and blood fat levels.
What is Tirzepatide used for?
Sold as Mounjaro and Zepbound, this is one of the most effective weight loss medications available. It works by targeting two appetite hormones at once (GIP and GLP-1), making it more powerful than medications like semaglutide that only target one. People in clinical trials lost up to 22.5% of their body weight. Also FDA-approved for type 2 diabetes, and improves cholesterol and blood fat levels.
What is the dosage for Tirzepatide?
Weight management (Zepbound): 2.5 mg subcutaneous once weekly for 4 weeks, increasing by 2.5 mg every 4 weeks to maintenance dose of 5-15 mg once weekly. Diabetes (Mounjaro): same escalation schedule, maintenance 5-15 mg subcutaneous once weekly.
What are the side effects of Tirzepatide?
Common: nausea (25-35%), diarrhea, constipation, vomiting, reduced appetite, stomach pain, redness at injection site. Serious: inflammation of the pancreas (pancreatitis), gallstones, very slow stomach emptying (gastroparesis), low blood sugar if combined with other diabetes medications. Rare: thyroid tumours seen in animal studies, severe allergic reactions, kidney problems.
How does Tirzepatide work?
Tirzepatide is the first approved dual incretin receptor agonist, simultaneously activating both GIP (glucose-dependent insulinotropic polypeptide) and GLP-1 receptors. This dual mechanism represents a paradigm shift in obesity and diabetes treatment because the two receptor systems produce complementary and additive metabolic effects that neither achieves alone. The GLP-1 receptor component works similarly to semaglutide — suppressing appetite through hypothalamic signaling, slowing gastric emptying, and stimulating glucose-dependent insulin secretion. However, the addition of GIP receptor agonism provides unique benefits. GIP receptors in adipose tissue enhance lipid metabolism and may improve fat storage efficiency, while GIP signaling in the brain appears to amplify the appetite-suppressing effects of GLP-1 through distinct neuronal circuits in the hypothalamus. At the pancreatic level, the dual stimulation of both GIP and GLP-1 receptors on beta cells produces a more robust insulin secretory response than either pathway alone. Tirzepatide also improves insulin sensitivity in peripheral tissues, reduces hepatic fat content, and lowers triglyceride levels. The molecule is built on a modified GIP peptide backbone with GLP-1 receptor cross-reactivity, attached to a C20 fatty di-acid moiety that enables albumin binding and weekly dosing. Clinical trials have shown weight loss of up to 22.5% of body weight, surpassing GLP-1-only agents.
How is Tirzepatide administered?
Tirzepatide is administered via subcutaneous injection (weekly).
What is the half-life of Tirzepatide?
The half-life of Tirzepatide is 120 hours (5 days).
Is Tirzepatide legal?
FDA approved. Mounjaro (2022), Zepbound (2023). Eli Lilly. Subject to intermittent supply shortages.
Related Peptides
5-Amino-1MQ
A pill that aims to switch fat cells from 'storage mode' to 'burning mode' by blocking an enzyme (NNMT) that is overactive in the fat tissue of overweight people. Not technically a peptide, but commonly sold alongside them. Unlike appetite suppressants, this targets the fat cells directly rather than making you eat less. The science is promising in lab studies, but there are no completed human trials yet.
Adipotide
An extreme experimental approach to fat loss — it physically destroys the blood vessels that feed fat tissue, starving fat cells until they die. Originally developed using anti-cancer technology at MD Anderson Cancer Center. While it did reduce fat in monkey studies, it also caused serious kidney damage, which has effectively stopped its development. Not available for human use.
AOD-9604
A small piece of human growth hormone (amino acids 176-191) designed to keep only the fat-burning effects while removing the unwanted side effects of full growth hormone (like swelling and blood sugar problems). The idea is promising — burn fat without the downsides — but it failed to show significant weight loss in clinical trials. Still widely used in research and wellness clinics despite the weak clinical evidence.
Cagrilintide
A long-acting version of amylin, a natural hormone your body releases after eating that tells your brain you're full. It works through a completely different pathway than GLP-1 drugs like semaglutide, which is why combining them (as CagriSema) produces even better results. On its own, it reduces how much you eat per meal by signalling fullness earlier. Developed by Novo Nordisk, mainly as part of the CagriSema combination.